|1.||Del Giudice, Giuseppe: 6 articles (05/2015 - 06/2009)|
|2.||Groth, Nicola: 5 articles (01/2014 - 11/2009)|
|3.||Rappuoli, Rino: 4 articles (01/2015 - 01/2009)|
|4.||Bernstein, David I: 4 articles (12/2014 - 03/2008)|
|5.||Hill, Heather: 4 articles (12/2014 - 03/2008)|
|6.||Della Cioppa, Giovanni: 4 articles (04/2014 - 11/2009)|
|7.||Knuf, Markus: 3 articles (01/2015 - 10/2011)|
|8.||Edupuganti, Srilatha: 3 articles (12/2014 - 10/2014)|
|9.||Rouphael, Nadine: 3 articles (12/2014 - 10/2014)|
|10.||Winokur, Patricia: 3 articles (12/2014 - 10/2014)|
|1.||Human Influenza (Influenza)
05/15/2015 - "The B cell adjuvanticity of MF59 appears to be mediated by the potent induction of TFH cells which directly controls GC responses both in adult and early life, calling for studies assessing its capacity to enhance the efficacy of influenza immunization in young infants. "
12/09/2013 - "An MF59 adjuvanted vaccine provided significantly improved protection against influenza in the elderly."
11/01/2006 - "The combination of MF59 adjuvant with a subunit vaccine was associated with improved immune responses to an influenza A/H9N2 virus. "
01/01/2013 - "Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study."
10/05/2012 - "A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic."
10/01/2007 - "MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection."
06/24/2009 - "MF59 adjuvant enhanced induction of clade-specific and cross-clade serum antibody responses, reduced frequency of infection (as determined by upper respiratory tract virus shedding and seroconversion data), and eliminated disease signs. "
12/01/2013 - "A vaccine comprised of recombinant gB protein with MF59 adjuvant reduced the incidence of primary infection by 50%. "
10/23/2008 - "The Towne vaccine and the gB/MF59 subunit vaccine induced epithelial entry-specific neutralizing activities that were on on average 28-fold (Towne) or 15-fold (gB/MF59) lower than those observed following natural infection. "
01/02/2004 - "Overall, the results suggest that the MF59/p24 vaccine better controls the infection in terms of viral replication and survival."
10/01/1998 - "In contrast, periocular vaccination with gB2/gD2 in MF59 provided significant protection against conjunctivitis and iritis, while ocular vaccination with live HSV-1 KOS provided significant protection against all four parameters. "
10/01/1998 - "Systemic vaccination with either HSV-1 KOS or gB2/gD2 in MF59 did not provide significant protection against any of the four eye disease parameters measured (conjunctivitis, iritis, epithelial keratitis, and corneal clouding). "
|5.||Eye Diseases (Eye Disease)
|2.||Influenza Vaccines (FluMist)
|3.||aluminum sulfate (alum)
|6.||Immunoglobulin G (IgG)
|9.||Aluminum Hydroxide (Algeldrate)
|2.||Transplantation (Transplant Recipients)